Europe Neoantigen Summit 2022
Presentation
Maik Pruess, PhD
Senior Field Application Scientist
Personalis, Inc.
April 27, 2022 | 10:10 AM GMT
Don’t miss what’s (ImmunoID) NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics, and Immunogenomics Profiling
- Accurate assessment of mutational landscape and putative neoantigens from the analytically-validated exome and transcriptome ImmunoID NeXT platform
- Improved neoantigen presentation and binding predictions through a machine learning algorithm, SHERPA, built upon high quality immunopeptidomics training data from mono-allelic, and multi-allelic samples
- Comprehensive immunogenomics profiling from a single sample to guide neoantigen-based therapies today and enable future biomarker discovery
Connect with us at Europe Neoantigen Summit 2022
